NCT05547542View on ClinicalTrials.gov

Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 2, 2023

Primary Completion Date

July 24, 2024

Study Completion Date

August 6, 2024

Conditions
Opioid Use Disorder
Interventions
DRUG

CVL-354

Oral solution/capsule

DRUG

[11C]-LY2795050

IV injection

DRUG

[11C]-carfentanil

IV injection

Trial Locations (2)

06510

New Haven, Connecticut, New Haven

Yale PET Center, New Haven

Sponsors
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Cerevel Therapeutics, LLC

INDUSTRY

NCT05547542 - Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing | Biotech Hunter | Biotech Hunter